Functional disruption of IEX-1 expression by concatemeric hammerhead ribozymes alters growth properties of 293 cells

FEBS Lett. 2001 Apr 13;494(3):196-200. doi: 10.1016/s0014-5793(01)02344-4.

Abstract

The early response gene IEX-1 modulates apoptosis and cell growth in a poorly defined fashion. Here, we describe the effect of hammerhead ribozymes specifically disrupting IEX-1 expression in 293 cells. Compared to vector control, 293 cells exhibit a reduced growth rate and a slowed cell cycle progression, when stably transfected with a concatemeric ribozyme construct. In addition, these 293 cells were much less sensitive to apoptosis induced by an activating Fas/CD95 antibody or by the anti-cancer drugs etoposide and doxorubicin. By modulating the cell cycle, IEX-1 might be part of a growth signal if favourable growth conditions prevail, whereas under unfavourable conditions, i.e. death receptor activation, IEX-1 facilitates apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Apoptosis Regulatory Proteins
  • Base Sequence
  • Cell Division / drug effects
  • Cell Line
  • Doxorubicin / pharmacology
  • Etoposide / pharmacology
  • Humans
  • Immediate-Early Proteins / biosynthesis
  • Immediate-Early Proteins / genetics
  • Immediate-Early Proteins / metabolism*
  • Membrane Glycoproteins / biosynthesis
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism*
  • Membrane Proteins
  • Neoplasm Proteins*
  • RNA, Catalytic / chemistry
  • RNA, Catalytic / genetics
  • RNA, Catalytic / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Templates, Genetic
  • Transfection
  • fas Receptor / metabolism

Substances

  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • IER3 protein, human
  • Immediate-Early Proteins
  • Membrane Glycoproteins
  • Membrane Proteins
  • Neoplasm Proteins
  • RNA, Catalytic
  • RNA, Messenger
  • fas Receptor
  • Etoposide
  • Doxorubicin